Wealth Alliance Advisory Group LLC decreased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,625 shares of the company’s stock after selling 745 shares during the period. Johnson & Johnson makes up 1.0% of Wealth Alliance Advisory Group LLC’s holdings, making the stock its 21st biggest holding. Wealth Alliance Advisory Group LLC’s holdings in Johnson & Johnson were worth $2,732,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. Scotia Capital Inc. raised its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock valued at $195,247,000 after purchasing an additional 17,440 shares during the period. Wisconsin Capital Management LLC raised its holdings in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock worth $2,437,000 after acquiring an additional 127 shares during the last quarter. Boyar Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 1.1% in the 1st quarter. Boyar Asset Management Inc. now owns 19,191 shares of the company’s stock worth $2,975,000 after acquiring an additional 201 shares during the last quarter. Van Hulzen Asset Management LLC raised its holdings in shares of Johnson & Johnson by 31.8% in the 1st quarter. Van Hulzen Asset Management LLC now owns 161,743 shares of the company’s stock worth $25,052,000 after acquiring an additional 39,032 shares during the last quarter. Finally, Duality Advisers LP acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $4,342,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analysts Set New Price Targets
JNJ has been the topic of a number of analyst reports. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. Barclays upped their price objective on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Monday, July 24th. Stifel Nicolaus upped their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Finally, StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $171.60.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The business had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the prior year, the company posted $2.59 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.76 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.84%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Insider Activity at Johnson & Johnson
In related news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock valued at $7,928,856. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- How to Invest in Cybersecurity
- Can the Amazon Partnership Put DISH Network Back on Track?
- Roth IRA Calculator: Calculate Your Potential Returns
- Snap Stock: Two Steps Forward and One Step Back In?
- There Are Different Types of Stock To Invest In
- ONSemi Is On Target For New Highs In 2023
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
